Back to News
Market Impact: 0.35
FDA Grants Rare Pediatric Disease Designation To Quoin's QRX003 For PSS
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
Quoin Pharmaceuticals received FDA Rare Pediatric Disease designation for QRX003, its treatment candidate for Peeling Skin Syndrome. The designation supports development of a therapy for a rare pediatric condition and could enhance the program's regulatory and commercial value, although no clinical efficacy or approval data were reported.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
QNRX0.75
More News
- Looters hit 3,000 French businesses. Within hours, the haul was trending on Vinted under the riot’s date
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- With earnings in rearview mirror, SpaceX-Tesla merger chatter takes center stage
- J&J prostate cancer drug shows promising tumor responses in early trial
- Piero Cipollone: Interview with Milano Finanza